Clinical Trial Detail

NCT ID NCT01884285
Title AZD8186 First Time In Patient Ascending Dose Study
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors AstraZeneca
Indications

triple-receptor negative breast cancer

non-small cell lung carcinoma

Advanced Solid Tumor

prostate cancer

Therapies

AZD8186

Abiraterone + AZD8186

AZD8186 + Vistusertib

Age Groups: senior adult

Additional content available in CKB BOOST